Table 4.
AORs with 95% CIs for association between α-tocopherol and NAFLD assessed using different prediction models.
| α-Tocopherol | NAFLD Assessed by HSI | NAFLD Assessed by FSI | NAFLD Assessed by CNS | ||||||
|---|---|---|---|---|---|---|---|---|---|
| AOR * | 95% CI | p-Value | AOR * | 95% CI | p-Value | AOR * | 95% CI | p-Value | |
|
All subjects
(n = 4448) |
|||||||||
| Q1 | 1 | 1 | 1 | ||||||
| Q2 | 1.14 | 0.80, 1.63 | 0.47 | 1.44 | 1.02, 2.03 | 0.04 | 1.37 | 0.99, 1.88 | 0.05 |
| Q3 | 1.30 | 0.92, 1.84 | 0.14 | 2.08 | 1.49, 2.91 | <0.001 | 2.32 | 1.68, 3.20 | <0.001 |
| Q4 | 1.44 | 1.01, 2.05 | 0.04 | 3.96 | 2.83, 5.56 | <0.001 | 3.39 | 2.44, 4.71 | <0.001 |
| p for trend | 0.03 | <0.001 | <0.001 | ||||||
|
Male subjects
(n = 1677) |
|||||||||
| Q1 | 1 | 1 | 1 | ||||||
| Q2 | 1.00 | 0.62, 1.61 | 0.99 | 1.58 | 1.00, 2.50 | 0.05 | 1.02 | 0.65, 1.62 | 0.92 |
| Q3 | 1.41 | 0.89, 2.23 | 0.14 | 1.93 | 1.24, 3.02 | 0.004 | 1.76 | 1.10, 2.81 | 0.02 |
| Q4 | 1.14 | 0.71, 1.81 | 0.59 | 4.34 | 2.76, 6.84 | <0.001 | 3.87 | 2.33, 6.84 | <0.001 |
| p for trend | 0.35 | <0.001 | <0.001 | ||||||
|
Female subjects
(n = 2771) |
|||||||||
| Q1 | 1 | 1 | 1 | ||||||
| Q2 | 1.38 | 0.76, 2.50 | 0.28 | 1.53 | 0.87, 2.69 | 0.14 | 1.71 | 1.08, 2.70 | 0.02 |
| Q3 | 1.72 | 0.98, 3.04 | 0.06 | 2.10 | 1.24, 3.53 | 0.006 | 2.66 | 1.69, 4.19 | <0.001 |
| Q4 | 2.02 | 1.14, 3.59 | 0.02 | 4.38 | 2.58, 7.45 | <0.001 | 3.39 | 2.16, 5.32 | <0.001 |
| p for trend | 0.01 | <0.001 | <0.001 | ||||||
* The logistic model was adjusted for age, sex, BMI, GFR, hypertension, diabetes, dyslipidemia status, income level, smoking status, alcohol consumption, exercise status, and use of vitamin supplements. NAFLD, non-alcoholic fatty liver disease; AOR, adjusted odds ratio; CI, confidence interval; HSI, hepatic steatosis index; FSI, Framingham steatosis index; CNS, comprehensive NAFLD score; BMI, body mass index; GFR, glomerular filtration rate.